About Simulations Plus
Simulations Plus is a company based in Lancaster (United States) founded in 1996.. The company has 197 employees as of August 31, 2023. Simulations Plus has completed 5 acquisitions, including Cognigen, DILIsym and DILIsym Services. Simulations Plus offers products and services including GastroPlus, ADMET Predictor, MonolixSuite, and DILIsym. Simulations Plus operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Lancaster, United States
- Employees 197 as on 31 Aug, 2023
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Simulations Plus, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Simulations Plus
Simulations Plus is a publicly listed company on the NASDAQ with ticker symbol SLP in USA, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Simulations Plus
Simulations Plus offers a comprehensive portfolio of products and services, including GastroPlus, ADMET Predictor, MonolixSuite, and DILIsym. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Simulates drug absorption and pharmacokinetics for development research.
Predicts metabolic properties using machine learning for drug safety.
Facilitates pharmacometrics modeling and simulation for clinical trials.
Models liver injury risks in drug development processes.
Unlock access to complete
Unlock access to complete
Funding Insights of Simulations Plus
- Total Funding Total Funding
- Total Rounds 9
- Last Round Last Round
-
First Round
First Round
(01 Jul 2007)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2024 | Amount | Grant - Simulations Plus | Valuation |
investors |
|
| Oct, 2024 | Amount | Grant - Simulations Plus | Valuation |
investors |
|
| Sep, 2024 | Amount | Grant - Simulations Plus | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Simulations Plus
Simulations Plus has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and U.S. Food and Drug Administration. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
The U.S. Food and Drug Administration is tasked with regulating food, drugs, and medical products.
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Simulations Plus
Simulations Plus has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Cognigen, DILIsym and DILIsym Services. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Quantitative toxicology software is provided for drug development processes.
|
2014 | ||||
|
Pharmaceutical, consulting, and concierge services are provided.
|
2014 | ||||
|
Modeling and simulation software for drug development is developed.
|
2011 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Simulations Plus
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Simulations Plus Comparisons
Competitors of Simulations Plus
Simulations Plus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Provider of cell therapies to treat cancer and hematologic conditions
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Simulations Plus
Frequently Asked Questions about Simulations Plus
When was Simulations Plus founded?
Simulations Plus was founded in 1996 and raised its 1st funding round 11 years after it was founded.
Where is Simulations Plus located?
Simulations Plus is headquartered in Lancaster, United States. It is registered at Lancaster, Pennsylvania, United States.
How many employees does Simulations Plus have?
As of Aug 31, 2023, the latest employee count at Simulations Plus is 197.
What is the annual revenue of Simulations Plus?
Annual revenue of Simulations Plus is $40.07M as on Aug 31, 2024.
What does Simulations Plus do?
Founded in 1996 and based in Lancaster, United States, Simulations Plus operates in the chemoinformatics and drug discovery sector. Eight software packages are offered, including GastroPlus for PKPD simulations in humans and animals, DDDPlus for formulation dissolution modeling, and ADMET Predictor for ADME property predictions. Additional tools support molecule sketching, data mining, and cloud storage. Services encompass regulatory strategies, pharmacometrics, and modeling solutions.
Who are the top competitors of Simulations Plus?
Simulations Plus's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Simulations Plus offer?
Simulations Plus offers GastroPlus, ADMET Predictor, MonolixSuite, and DILIsym.
Is Simulations Plus publicly traded?
Yes, Simulations Plus is publicly traded on NASDAQ under the ticker symbol SLP.
How many acquisitions has Simulations Plus made?
Simulations Plus has made 5 acquisitions, including Cognigen, DILIsym, and DILIsym Services.
Who are Simulations Plus's investors?
Simulations Plus has 3 investors. Key investors include NIH, HHS, and U.S. Food and Drug Administration.
What is Simulations Plus's ticker symbol?
The ticker symbol of Simulations Plus is SLP on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.